Hou Hua, Xu Yujia, Chen Guangxin, Yao Haifeng, Bi Fangjie
School of Clinical Medicine, Binzhou Medical University, Binzhou, Shandong, People's Republic of China.
Department of Echocardiography, Zibo Central Hospital, Zibo, Shandong, People's Republic of China.
J Inflamm Res. 2024 Nov 6;17:8281-8298. doi: 10.2147/JIR.S482596. eCollection 2024.
The Systemic Inflammation Response Index (SIRI) and N-terminal Pro-B-type natriuretic peptide (NT-proBNP) have been proposed as reliable predictors of poor prognosis in cardiovascular disease and all-cause mortality, However, their validity has not been extensively evaluated in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA).
259 patients diagnosed with MINOCA were enrolled in this study from January 2015 to December 2022, and serum levels of SIRI and NT-proBNP were detected. The primary endpoints were major adverse cardiovascular events (MACE). According to the occurrence of MACE during the follow-up period, patients were grouped into MACE and Non-MACE groups, and divided by the median values for SIRI and NT-proBNP into groups: low SIRI, high SIRI, low NT-proBNP, and high NT-proBNP.
A statistically significant difference in the levels of SIRI and NT-proBNP was observed between the MACE group and the non-MACE group. Kaplan-Meier survival curve analysis revealed that patients with high SIRI and high NT-proBNP had a significantly higher risk of MACE (log-rank P < 0.001). Furthermore, even after adjusting for covariates, the high SIRI and high NT-proBNP were associated with an increased risk of MACE (P<0.001, HR: 3.188, 95% CI 1.940-5.241; P<0.001, HR: 2.245, 95% CI 1.432-3.519). Additionally, the combined prognosis prediction of SIRI and NT-proBNP was superior to a single prediction, and adding SIRI and NT-proBNP to the traditional risk factor model improved the model's predictive value.
High levels of SIRI and NT-proBNP exhibit a significant correlation with an increased risk of MACE, thereby suggesting that SIRI can be used as a reliable inflammatory indicator for predicting the risk in MINOCA patients, with significantly improved prognostic value when combined with NT-proBNP.
全身炎症反应指数(SIRI)和N端前脑钠肽(NT-proBNP)已被认为是心血管疾病不良预后和全因死亡率的可靠预测指标。然而,它们在非阻塞性冠状动脉心肌梗死(MINOCA)患者中的有效性尚未得到广泛评估。
2015年1月至2022年12月,本研究纳入了259例诊断为MINOCA的患者,并检测了血清SIRI和NT-proBNP水平。主要终点是主要不良心血管事件(MACE)。根据随访期间MACE的发生情况,将患者分为MACE组和非MACE组,并根据SIRI和NT-proBNP的中位数分为低SIRI、高SIRI、低NT-proBNP和高NT-proBNP组。
MACE组和非MACE组之间SIRI和NT-proBNP水平存在统计学显著差异。Kaplan-Meier生存曲线分析显示,高SIRI和高NT-proBNP患者发生MACE的风险显著更高(对数秩检验P<0.001)。此外,即使在调整协变量后,高SIRI和高NT-proBNP仍与MACE风险增加相关(P<0.001,HR:3.188,95%CI 1.940-5.241;P<0.001,HR:2.245,95%CI 1.432-3.519)。此外,SIRI和NT-proBNP的联合预后预测优于单一预测,将SIRI和NT-proBNP添加到传统风险因素模型中可提高模型的预测价值。
高SIRI和NT-proBNP水平与MACE风险增加显著相关,这表明SIRI可作为预测MINOCA患者风险的可靠炎症指标,与NT-proBNP联合使用时预后价值显著提高。